Insomnia market to grow through 2036 driven by novel orexin and melatonin therapies

Industry
โดย DelveInsight·Read original
Summary · why it matters

The global insomnia treatment market is projected to grow robustly through 2036, fueled by rising disease awareness and a pipeline of emerging therapies. In 2025, diagnosed prevalent cases of insomnia across the seven major markets—the United States, the EU4, the United Kingdom, and Japan—were estimated at approximately 90 million, with the United States accounting for the largest market share. Key pipeline candidates include Johnson & Johnson's Seltorexant, Vanda Pharmaceuticals' HETLIOZ, Idorsia's Daridorexant, and EUSOL Biotech's SM-1, which are expected to reshape the competitive landscape alongside recently approved orexin receptor antagonists such as VORZZZ in Japan. The market is also benefiting from the launch of novel drug classes like orexin antagonists and melatonin agonists, as well as increased adoption of cognitive behavioral therapy for insomnia.

Impact on stocks 3

Biotech & Genomic Medicine▲ · 3 stocks
Idorsia Ltd
IDIA
▲ PositiveDemandrelevance

Idorsia's Daridorexant is a key pipeline candidate in a growing insomnia market.

Johnson & Johnson
JNJ
▲ PositiveDemandrelevance

Johnson & Johnson's Seltorexant is a key pipeline candidate expected to benefit from growing insomnia market.

Off-coverage companies 1

Eusol Biotech Co., Ltd.Private▲ Positive
Demandrelevance

EUSOL Biotech's SM-1 is a key pipeline candidate in a growing insomnia market.

© 2026 MarketDXNews